Indivior PLC Settlement with Dr. Reddy's Laboratories (1434Q)
June 24 2022 - 6:45AM
UK Regulatory
TIDMINDV
RNS Number : 1434Q
Indivior PLC
24 June 2022
Indivior Reaches Settlement with Dr. Reddy's Laboratories in
Patent Infringement Case
Slough, UK and Richmond, VA, June 24, 2022 - Indivior PLC, (LON:
INDV) announced that together with Aquestive Therapeutics, Inc. it
entered into a settlement agreement with Dr. Reddy's Laboratories
Ltd. (DRL) and its subsidiaries resolving patent litigation
relating to DRL's generic buprenorphine and naloxone sublingual
film, a therapeutic equivalent generic version of SUBOXONE(R)
(buprenorphine and naloxone) sublingual film. The confidential
settlement resolves all claims between the parties and the amount
paid by Indivior to DRL pursuant to the settlement is consistent
with its previously disclosed reserve amount.
About Indivior
Indivior is a global pharmaceutical company working to help
change patients' lives by developing medicines to treat substance
use disorders (SUD) and serious mental illnesses. Our vision is
that all patients around the world will have access to
evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD,
including alcohol use disorder and cannabis use disorder.
Headquartered in the United States in Richmond, VA, Indivior
employs more than 900 individuals globally and its portfolio of
products is available in over 40 countries worldwide. Visit
www.indivior.com to learn more. Connect with Indivior on
LinkedIn by visiting www.linkedin.com/company/indivior .
For Further Information
Jason Thompson VP, Investor +1 804 402 7123
Relations jason.thompson@indivior.com
Indivior PLC
Tim Owens Director, Investor +1 804 263 3978
Relations Indivior timothy.owens@indivior.com
PLC
-ends-
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDBKQBQKBKDNAB
(END) Dow Jones Newswires
June 24, 2022 06:45 ET (10:45 GMT)
Indivior (LSE:INDV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Indivior (LSE:INDV)
Historical Stock Chart
From Sep 2023 to Sep 2024